Text Size

Recovery Management Intervention in China

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01270100
First received: January 4, 2011
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

The purpose of the study is to develop and pilot-test a Recovery Management Intervention (RMI) program for heroin addicts released from compulsory rehabilitation in China.

The project has the following specific aims:

Primary aims:

Aim 1. To engage key stakeholders in the local communities involved in supporting the transition of heroin addicts released from compulsory rehabilitation to the community; Aim 2. To identify potential barriers for participating in MMT in China; Aim 3. To develop and deliver educational/training materials on HIV risks, relapse prevention, and MMT; Aim 4. To adapt and develop the Recovery Management Intervention (RMI) program for heroin addicts released from compulsory rehabilitation in China; Aim 5. To conduct a pilot trial and obtain preliminary outcome data associated with RMI, relative to enhanced standard care.

Secondary aim:

Aim 6. To explore predictors of relapse and HIV/AIDS risk behaviors.

It is hypothesized that the intervention will reduce drug use relapse and the negative consequences associated with relapse, including HIV risk behaviors


Condition Intervention
Methadone
HIV Infections
 Behavioral: Recovery management

Study Type: Interventional
Official Title: Reducing HIV/AIDS and Drug Abuse Among Heroin Addicts Released From Compulsory Rehabilitation in China

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Arms Assigned Interventions
Experimental: Recovery management intervention Behavioral: Recovery management

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:The study population will be drawn from all adult patients at participating compulsory rehabilitation facilities who:

  1. have been incarcerated for at least one year and would have been eligible for MMT at the time of incarceration,
  2. have at least 1 month remaining before release,
  3. met the DSM-IV criteria for heroin dependence at the time of incarceration,
  4. are willing to enroll in methadone maintenance treatment, and
  5. are Shanghai residents who reside in the areas of Shanghai targeted by the study.

Exclusion Criteria: Individuals diagnosed with severe mental illness will not be eligible to participate.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01270100

Locations
China
Shanghai Mental Health Center
Shanghai, China
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
  More Information

No publications provided by University of California, Los Angeles

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT01270100     History of Changes
Other Study ID Numbers: DA025385, 1R21DA025385-01
Study First Received: January 4, 2011
Last Updated: January 4, 2011
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on May 22, 2013